Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2004, for Phase III Medical, Inc. (formerly Corniche Group Incorporated). The company provides capital and guidance to medical sector companies in exchange for royalty interests. Its current operations consist of the "run off" of an internet-based extended warranty business and new ventures in the medical/bio-tech sector, specifically a royalty agreement with Parallel Solutions, Inc. (PSI) and a joint venture with NeoStem, Inc.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Revenue | $27,342 | $18,004 |
| Gross Profit | $8,069 | $5,081 |
| Operating Loss | $(381,014) | $(123,497) |
| Net Loss | $(456,206) | $(142,980) |
| Net Loss Per Share (Basic) | $(0.02) | $(0.01) |
| Cash and Equivalents (End of Period) | $23,645 | $14,877 |
| Net Cash Used in Operating Activities | $(396,225) | $(59,075) |
| Total Current Liabilities | $1,198,065 | N/A |
| Notes Payable (Current) | $520,000 | N/A |
Note: The company reported a significant "Purchase of medical royalty stream" expense of $240,000 in Q1 2004, which was not present in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Earned revenues increased by approximately 52% to $27,342, driven by the run-off of prior warranty contracts.
- Expense Surge: Operating loss widened significantly to $(381,014) from $(123,497). This was primarily due to a one-time $240,000 payment for the purchase of a medical royalty stream and a 15.9% increase in selling, general, and administrative (SG&A) expenses to $149,083.
- Interest Expense: Interest expense increased by approximately $44,000 to $63,430 due to new short-term loans and higher rates on defaulted notes.
- Liquidity Decline: Cash and cash equivalents decreased by $187,302 during the quarter, leaving the company with only $23,645 at period end.
Outlook, Risks, and Contingencies
- Going Concern: Management explicitly states that the company has limited financial resources to pay current expenses and liabilities, raising "substantial doubt" about its ability to continue as a going concern.
- Debt Defaults: The company is in default on multiple promissory notes totaling over $500,000. Default penalties include the option for holders to purchase common stock at significantly discounted rates ($125 for 25,000 shares).
- Capital Requirements: The company has a contractual commitment to pay an additional $680,000 to PSI under its royalty agreement. It plans to fund operations and obligations through an amended equity private placement (targeting up to $4 million) and additional loans from accredited investors.
- Unusual Items: The $240,000 royalty purchase was charged to current operations due to uncertainty regarding future revenue generation from the investment.
Investor Verification Checklist
- Cash Runway: Verify if the $23,645 cash balance is sufficient to cover immediate payroll and the $680,000 remaining obligation to PSI.
- Debt Dilution: Assess the potential dilution from 875,000 shares reserved for note holders exercising default options and the 200,000 shares already exercised in the quarter.
- Capital Raise Status: Confirm the progress of the amended equity private placement and the $175,000 in proceeds raised subsequent to March 31, 2004.
- Revenue Realization: Monitor whether the royalty agreement with PSI or the joint venture with NeoStem generates any actual revenue, as current operations are loss-making.